Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liver warning for Tarceva expanded

This article was originally published in Scrip

Executive Summary

Genentechand OSI Pharmaceuticals have alerted US physicians to cases of hepatic failure and hepatorenal syndrome, including fatalities, associated with use of the anticancer Tarceva (erlotinib), particularly in patients with baseline hepatic impairment. Close monitoring of those with such impairment is advised. The EGFR-targeted drug is approved as a second-line treatment in advanced non-small cell lung cancer (NSCLC) and in advanced pancreatic cancer, and is in trials in a number of other tumour types.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel